{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:49Z","timestamp":1790698909138,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease. However, owing to better efficacy and safety of combination antiretroviral therapy (cART), and increased access to HCV therapy, whether this condition remains true is still unknown. Overall, 1,253 HCV mono\u2010infected patients and 175 HIV\/HCV co\u2010infected patients with cirrhosis, included in two prospective French national cohorts (ANRS CO12 CirVir and CO13 HEPAVIH), were studied. Cirrhosis was compensated (Child\u2010Pugh A), without past history of complication, and assessed on liver biopsy. Incidences of liver decompensation (LD), hepatocellular carcinoma (HCC), and death according to HIV status were calculated by a Fine\u2010Gray model adjusted for age. Propensity score matching was also performed to minimize confounding by baseline characteristics. At baseline, HIV\/HCV patients were younger (47.5 vs. 56.0 years; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001), more frequently males (77.1% vs. 62.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001), and had at baseline and at end of follow\u2010up similar rates of HCV eradication than HCV mono\u2010infected patients. A total of 80.4% of HIV\/HCV patients had an undetectable HIV viral load. After adjustment for age, 5\u2010year cumulative incidences of HCC and decompensation were similar in HIV\/HCV and HCV patients (8.5% vs. 13.2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.12 and 12.8% vs. 15.6%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.40, respectively). Overall mortality adjusted for age was higher in HIV\/HCV co\u2010infected patients (subhazard ratio [SHR] = 1.88; 95% confidence interval [CI], 1.15\u20103.06; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.011). Factors associated with LD and HCC were age, absence of sustained virological response, and severity of cirrhosis, but not HIV status. Using a propensity score matching 95 patients of each group according to baseline features, similar results were observed. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: In HCV\u2010infected patients with cirrhosis, HIV co\u2010infection was no longer associated with higher risks of HCC and hepatic decompensation. Increased mortality, however, persisted, attributed to extrahepatic conditions.<\/jats:p>","DOI":"10.1002\/hep.30400","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T06:20:55Z","timestamp":1545286855000},"page":"939-954","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Human Immunodeficiency Virus\/Hepatitis C Virus (HCV) Co\u2010infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End\u2010Stage Liver Disease as Compared to HCV Mono\u2010infected Patients"],"prefix":"10.1097","volume":"70","author":[{"given":"Dominique","family":"Salmon\u2010Ceron","sequence":"first","affiliation":[{"name":"APHP, H\u00f4pitaux Universitaires Paris Centre, Infectious Diseases Federation,Paris,France"},{"name":"Paris Descartes University,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Jean Verdier, Hepatology Department,Bondy,France"},{"name":"Paris 13 University, Sorbonne Paris Cit\u00e9, \u201cEquipe Labellis\u00e9e Ligue Contre le Cancer,\u201d Saint\u2010Denis, and Inserm UMR 1162,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Layese","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Public Health Department,94000,Cr\u00e9teil,France"},{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Clinical Research Unit (URC\u2010Mondor),94000,Cr\u00e9teil,France"},{"name":"Universit\u00e9 Paris\u2010Est, UPEC, DHU A\u2010TVB, IMRB\u2010EA CEpiA (Clinical Epidemiology and Ageing) Unit EA7376,94000,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bourcier","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Jean Verdier, Hepatology Department,Bondy,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[{"name":"Paris Descartes University,Paris,France"},{"name":"INSERM U\u20101223, Institut Pasteur and APHP, H\u00f4pitaux Universitaires Paris Centre, Hepatology Department,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouze","family":"Bani\u2010Sadr","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Reims, Internal Medicine Department,Infectious Diseases and Clinical Immunology Unit,Reims,France"},{"name":"Reims University,Champagne\u2010Ardenne,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Public Health Department,94000,Cr\u00e9teil,France"},{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Clinical Research Unit (URC\u2010Mondor),94000,Cr\u00e9teil,France"},{"name":"Universit\u00e9 Paris\u2010Est, UPEC, DHU A\u2010TVB, IMRB\u2010EA CEpiA (Clinical Epidemiology and Ageing) Unit EA7376,94000,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Merchadou","sequence":"additional","affiliation":[{"name":"Bordeaux University, ISPED, Inserm, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC\u2010EC 1401,F\u201033000,Bordeaux,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dabis","sequence":"additional","affiliation":[{"name":"Bordeaux University, ISPED, Inserm, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC\u2010EC 1401,F\u201033000,Bordeaux,France"},{"name":"CHU de Bordeaux, Public Health and Medical Information Department,F\u201033000,Bordeaux,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[{"name":"Bordeaux University, ISPED, Inserm, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC\u2010EC 1401,F\u201033000,Bordeaux,France"},{"name":"CHU de Bordeaux, Public Health and Medical Information Department,F\u201033000,Bordeaux,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roudot\u2010Thoraval","sequence":"additional","affiliation":[{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Public Health Department,94000,Cr\u00e9teil,France"},{"name":"AP\u2010HP, H\u00f4pital Henri\u2010Mondor, Clinical Research Unit (URC\u2010Mondor),94000,Cr\u00e9teil,France"},{"name":"Universit\u00e9 Paris\u2010Est, UPEC, DHU A\u2010TVB, IMRB\u2010EA CEpiA (Clinical Epidemiology and Ageing) Unit EA7376,94000,Cr\u00e9teil,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"hep30400-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co\u2010infection in people living with HIV: a global systematic review and meta\u2010analysis","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"hep30400-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus\/hepatitis C virus","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep30400-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","year":"1999","journal-title":"Hepatology"},{"key":"hep30400-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/319256","article-title":"Multicenter evaluation of hepatitis C RNA levels among female injection drug users","volume":"183","year":"2001","journal-title":"J Infect Dis"},{"key":"hep30400-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","article-title":"Human immunodeficiency virus\u2010related microbial translocation and progression of hepatitis C","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep30400-bib-0006-20241017","first-page":"e307","article-title":"Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV\/HCV\u2010coinfected patients","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"key":"hep30400-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/498312","article-title":"Progression of fibrosis in HIV and hepatitis C virus\u2010coinfected patients treated with interferon plus ribavirin\u2010based therapy: analysis of risk factors","volume":"41","year":"2005","journal-title":"Clin Infect Dis"},{"key":"hep30400-bib-0008-20241017","first-page":"328","article-title":"Mechanisms of accelerated liver fibrosis progression during HIV infection","volume":"4","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"hep30400-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta\u2010analysis","volume":"33","year":"2001","journal-title":"Clin Infect Dis"},{"key":"hep30400-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3748\/wjg.15.996","article-title":"Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta\u2010analysis","volume":"15","year":"2009","journal-title":"World J Gastroenterol"},{"key":"hep30400-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hiv.12322","article-title":"Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV\u2010positive persons","volume":"17","year":"2016","journal-title":"HIV Med"},{"key":"hep30400-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3851\/IMP2419","article-title":"Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV\u2010HCV\u2010coinfected patients: study from the ANRS CO 13 HEPAVIH cohort","volume":"17","year":"2012","journal-title":"Antivir Ther"},{"key":"hep30400-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"e4091","DOI":"10.1097\/MD.0000000000004091","article-title":"Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T\u2010cell count and NRTI exposure from a large cohort of HIV\/HCV\u2010coinfected patients with detectable HCV\u2010RNA: a MASTER cohort study","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"hep30400-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.27743","article-title":"Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep30400-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2334-10-303","article-title":"The French national prospective cohort of patients co\u2010infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006\u20102010","volume":"10","year":"2010","journal-title":"BMC Infect Dis"},{"key":"hep30400-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","year":"2005","journal-title":"Hepatology"},{"key":"hep30400-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/498312","article-title":"Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon\u2010ribavirin combination","volume":"41","year":"2005","journal-title":"Clin Infect Dis"},{"key":"hep30400-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV\u2010infected patients: a U.S.\u2010Canadian multicenter study","volume":"47","year":"2007","journal-title":"J Hepatol"},{"key":"hep30400-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clinre.2011.11.002","article-title":"Primary liver cancer is more aggressive in HIV\u2010HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir)","volume":"36","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"hep30400-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV\u20101","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep30400-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) in patients with hepatitis C virus and HIV coinfection (C\u2010EDGE COINFECTION): a non\u2010randomised, open\u2010label trial","volume":"2","year":"2015","journal-title":"Lancet HIV"},{"key":"hep30400-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co\u2010dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co\u2010infected with HIV\u20101: a randomized trial","volume":"313","year":"2015","journal-title":"JAMA"},{"key":"hep30400-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","year":"2014","journal-title":"JAMA"},{"key":"hep30400-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV\u20101","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep30400-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","article-title":". Efficacy and safety of direct\u2010acting antiviral regimens in HIV\/HCV\u2010co\u2010infected patients\u2014French ANRS CO13 HEPAVIH cohort","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30400-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non\u2010liver complications","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"hep30400-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:08:41Z","timestamp":1729210121000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30400","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"2018-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}